Innoviva, Inc. (INVA)

NASDAQ: INVA · Real-Time Price · USD
21.58
+0.41 (1.94%)
At close: Jun 6, 2025, 4:00 PM
21.04
-0.54 (-2.50%)
After-hours: Jun 6, 2025, 5:23 PM EDT
1.94%
Market Cap 1.35B
Revenue (ttm) 369.84M
Net Income (ttm) -59.72M
Shares Out 62.78M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE 18.41
Dividend n/a
Ex-Dividend Date n/a
Volume 1,154,765
Open 21.21
Previous Close 21.17
Day's Range 21.17 - 21.60
52-Week Range 15.56 - 21.60
Beta 0.37
Analysts Buy
Price Target 55.00 (+154.87%)
Earnings Date Jul 30, 2025

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2004
Employees 127
Stock Exchange NASDAQ
Ticker Symbol INVA
Full Company Profile

Financial Performance

In 2024, Innoviva's revenue was $358.71 million, an increase of 15.54% compared to the previous year's $310.46 million. Earnings were $23.39 million, a decrease of -86.98%.

Financial Statements

Analyst Forecast

According to one analyst, the rating for INVA stock is "Buy" and the 12-month stock price forecast is $55.0.

Price Target
$55.0
(154.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

4 days ago - Business Wire

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobipro...

18 days ago - Business Wire

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and...

18 days ago - GlobeNewsWire

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

4 weeks ago - Business Wire

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES , March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or...

Other symbols: ARMP
3 months ago - PRNewsWire

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

3 months ago - Business Wire

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

3 months ago - Business Wire

Innoviva: Underappreciated Strength In Hospital Therapeutics

Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The com...

3 months ago - Seeking Alpha

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

4 months ago - Business Wire

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and lic...

6 months ago - Business Wire

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...

6 months ago - GlobeNewsWire

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

6 months ago - Business Wire

Innoviva to Participate in the UBS Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

7 months ago - Business Wire

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

7 months ago - Business Wire

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the...

8 months ago - Business Wire

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

11 months ago - Business Wire

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.

Other symbols: GSK
1 year ago - Benzinga

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

Innoviva to Participate in the BofA Securities Health Care Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial wi...

1 year ago - Business Wire

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 2024 /PRNewswire/ -- Armata Pharmaceuti...

Other symbols: ARMP
1 year ago - PRNewsWire

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

1 year ago - Business Wire

10 stocks you can bet on being inflation-proof

New research shows that “quality” stocks — companies with high operating profitability but which are out of favor on Wall Street — are the type of stocks most likely to do well if inflation heats up. ...

Other symbols: AMCWCXWHCCOTTRPCARRDN
1 year ago - Market Watch

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reporte...

1 year ago - Business Wire